Related Experiment Video
Updated: Sep 19, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
Yue Zhang1, Rushan Xia1,2
1Department of Dermatology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, People's Republic of China.
Abstract:
This article reports a 59-year-old female patient who was diagnosed with segmental hyaline vasculitis and treated with tofacitinib for 2 months. In this case, multiple dark purplish-red spots were seen on both lower limbs, which did not fade with pressure. Flaky dark red spots, petechiae, ulcers, and necrosis were seen on the ankles. Histopathological manifestations were consistent with segmental hyaline vasculitis. The lesions subsided after the patient was treated with oral tofacitinib 5 mg twice daily for 1 month.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Related Concept Videos
The JAK-STAT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Nephrotic Syndrome II : Assessment and Medical Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome I : Introduction